Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Rebecca Tidswell und 7 weiteren Autor:innen. Beteiligte Einrichtung: Arthur Child Comprehensive Cancer Centre, Calgary, Canada. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Antineoplastic Combined Chemotherapy Protocols, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Novel targeted agents have transformed the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including continuous BTK inhibitor (BTKi) therapy and time‐limited regimens such as venetoclax‐obinutuzumab (Ven‐O) and ibrutinib‐venetoclax (I + V). However, factors guiding first‐line treatment decisions in routine practice remain poorly defined.
Objectives
To describe real‐world first‐line treatment patterns and identify factors associated with therapy selection.
Methods
This retrospective, population‐based study included consecutive patients initiating first‐line therapy for CLL/SLL in 2024 in Alberta, Canada.
Results
Among 148 patients with median age 71 years, time‐limited targeted therapy was selected for 75 (51%), including Ven‐O ( n = 73) and I + V ( n = 2). Continuous BTKi therapy was used in 65 (44%), while chemotherapy‐based regimens were uncommon ( n = 8, 5%). Among 138 patients treated with either continuous BTKi or Ven‐O, BTKi use was significantly more frequent among those with del(17p)/ TP53 mutation (84% vs. 16%, p = 0.0002), age > 75 years (66% vs. 34%, p = 0.0051), and residence > 100 km from an obinutuzumab‐initiating cancer center (70% vs. 30%, p = 0.031).
Conclusions
Time‐limited and continuous targeted therapies are used with similar frequency for CLL/SLL, with selection shaped by age, TP53 aberrations, geography, and patient preferences. These findings highlight the importance of personalized care and the need to reduce access barriers to time‐limited strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arthur Child Comprehensive Cancer Centre, Calgary, Canada.
- University of Calgary, Calgary, Canada.
- Cross Cancer Institute, Edmonton, Canada.
- University of Alberta, Edmonton, Canada.
ORCID-Profile: Carolyn Owen, Robert Puckrin
Zitieren
APA
Tidswell, R., Owen, C., Shafey, M., Perry, S., Cox-Kennett, N., Sterrett, R., Peters, A., & Puckrin, R. (2026). Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. European Journal of Haematology. https://doi.org/10.1111/ejh.70137
Vancouver
Tidswell R, Owen C, Shafey M, Perry S, Cox-Kennett N, Sterrett R, et al. Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. European Journal of Haematology. 2026. doi:10.1111/ejh.70137
BibTeX
@article{Tidswell2026,
author = {Tidswell, Rebecca and Owen, Carolyn and Shafey, Mona and Perry, Sarah and Cox-Kennett, Nanette and Sterrett, Russell and Peters, Anthea and Puckrin, Robert},
title = {Real‐World Selection of Venetoclax‐Obinutuzumab Versus BTK Inhibitor Therapy for Treatment‐Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70137}
}
EUVIMED